PO.ET07.01 · 实验与分子治疗
Quantitative Pharmacology and Translational Modeling
-
-
- 1815 1815 Nonclinical characterization of SBE303: A nectin-4 targeted antibody drug conjugate (ADC) with novel topoisomerase 1 inhibitor shows a favorable safety margin Ji Yeon Kim, Sungwoo Hyung, Hyun-Ji Choi, Songhyun Lim, Jae Hee Lee, Seokuee Kim, Donghyun Kim, So-Shin Ahn, Donghoon Shin
-
-
- 1819 1819 OBI-904, a glycan-based site-specific Nectin-4-targeted ADC, demonstrates potent and durable antitumor activity with an improved PK profile and overcoming EV-resistance in non-clinical studies Chi-Huan Lu, Ren-Yu Hsu, Jing-Jie Ciou, Tzu-Min Yen, Jyy-Shiuan Tu, Yu-Hsuan Tsao, Jing-Rong Huang, Ya-Chi Chen
- 1820 1820 Pharmacokinetic-tumor growth inhibition modeling of raludotatug deruxtecan (R-DXd) to support phase 3 dose selection in platinum-resistant ovarian cancer (PROC) YoungJun Yoo, Kevin Koloskoff, Sandra Re, Izna Ali, Felipe K. Hurtado, Raouf El Cheikh
- 1821 1821 Preclinical efficacy and safety of CS5006, a novel integrin beta4-targeting antibody-drug conjugate with a topoisomerase 1 inhibitor payload Chuan Wang, Xinling Zhang, Ning Zhang, Yamin Wang, Yongwang Li, Mengyao Zhu, Xuelian Liu, Yaxin Chen, Yuxin Qian, Yongli Yang, Jingyu Sun, Fei Ma, Jianxin Yang
- 1822 1822 Preclinical efficacy and safety of CS5008, a novel SSTR2×DLL3 bispecific antibody-drug conjugate (ADC) with topoisomerase 1 inhibitor payload for small cell lung cancer and neuroendocrine tumors Chuan Wang, Yongwang Li, Ning Zhang, Yamin Wang, Xinling Zhang, Xuelian Liu, Yuxin Qian, Hui Dai, Xueqin Dai, Yaxin Chen, Zicong Zheng, Wenjing Xiang, Fei Ma, Jianxin Yang
- 1823 1823 Preclinical efficacy and safety of CS5007, an EGFR×HER3 dual-targeting antibody-drug conjugate with a topoisomerase 1 inhibitor payload Chuan Wang, Yamin Wang, Ning Zhang, Xinling Zhang, Yongwang Li, Yuxin Qian, Yaxin Chen, Yongli Yang, Xuelian Liu, Mengyao Zhu, Hui Dai, Wenjing Xiang, Xueqin Dai, Fei Ma, Jianxin Yang
-
-
- 1826 1826 Exposure-response analysis and quantitative systems pharmacology modeling for an optimal dose selection of surovatamig in patients with DLBCL Xu (Sue) Zhu, Damilola Olabode, Massimo Lai, Cesar Pichardo-Almarza, Meenu Pillai, Denise Brennan, David Sermer, Robin Lesley
-
- 1828 1828 Preclinical evaluation of selective and potent EP300 degraders demonstrates robust antitumor activity and favorable tolerability in hematologic malignancies Meiyun Lin, Wesley Austin, Qianhe Zhuo, Rieko Arimoto, Karolina Mizeracka, Abira Ramakrishnan, Kevin Wilson, Elizabeth Wittenborn, Laura La Bonte, Steven Bellon
-
- 1830 1830 SP09253, an orally bioavailable, highly potent RAS(ON) molecular glue inhibitor demonstrates robust anti-tumor activity in KRAS-mutant tumors Zherong Zhang, Xiaoyu Di, Qiming Sun
-
- 1832 1832 In silico calmodulin-PCAIs binding affinities versus in vitro anticancer cell viability: Strategies for the development of anti-pan-mutant KRAS agents Jahnissi Frimpomah Odoom, Kweku Ofosu-Asante, Joshua Kofi Ablordeppey, Desmond Kwakye, Amarender Burra, Nazarius Lamango
- 1833 1833 Polyisoprenylated cysteinyl amide inhibitors suppress growth, induce cytoskeletal and transcriptomic remodeling in multiple KRAS -mutated lung cancer cells Desmond Kwakye, Chase Lilly, Kweku Ofosu-Asante, Jahnissi Frimpomah Odoom, Joshua Kofi Ablordeppey, Bianca Dal Bó, KARLA GONZALEZ, Chunli Yan, Matthew A. Gladstone, Kyle R. Phillips, Benjamin J. Ryder, Yong Huang, Ite A. Offringa, Nazarius Lamango
-
- 1835 1835 Evaluation of busulfan stability in infusion bags and biological matrix: Application to routine therapeutic drug monitoring with adaptive dosing in children Marielle Jehanno, Jasmine Bettayeb, Guillaume Sicard, Arthur Sterin, Joseph Ciccolini
-
- 1837 1837 Targeting Hippo/YAP-TEAD increases the antitumor activity of darovasertib in uveal melanoma Rodolfo Daniel Cervantes-Villagrana, Elena Sofia Cardenas Alcoser, Kuniaki Sato, Simone Lubrano, Tomohiko Ishikawa, Andrew E. Aplin, J. Silvio Gutkind
-
